Correlación entre los niveles plasmáticos de SLPI y la capacidad linfoproliferativa en pacientes con patologías pulmonares

REITERI, M; TATEOSIAN, NANCY; BARRO, A; GUERRIERI, D; AMIANO, N; MAZZEI, A; CHULUYAN, E

Argentina

Congreso; LV Reunión anual de la Sociedad Argentina de Inmunología; 2007

SAI

Rationale: Uterine serine proteinase inhibitor produced by epithelium inhibits a mitogen-induced lymphocyte proliferation.  SLPI, a serine proteinase inhibitor produced by lung epithelial cells, is present in exhaled breath condensate and serum of patients with lung pathology.  Objectives: the aim of the present study was to evaluate a putative correlation between SLPI levels and the proliferative ability of lymphocytes in response to mitogens.  Methods: SLPI plasma levels and the lymphoproliferative ability (?) were examined in healthy donors (HD; n =15), chronic obstructive pulmonary disease (COPD, n =17) and lung cancer (n = 23) patients.  In vitro, peripheral blood mononuclear cells (PBMC) were treated with mitogens plus rhSLPI and proliferation was assessed by 3H-thymidine up-take.  Plasma SLPI and cytokines were measured by ELISA and BD CBA cytokine array kit, respectively.  Furthermore, IkB was determined by Western blot.  Measurements and Main Results:  we observed a correlation between lymphocyte proliferation and plasma SLPI levels of lung cancer and COPD patients (r = -0.59, p<0.0001).  In vitro, rhSLPI decreased the lymphocyte proliferation induced by IL-2 in a dose-dependent manner.  Inhibition was not observed by depleting monocytes from the PBMC and it was restored by adding either SLPI-pretreated monocytes or SLPI-preteated monocytes culture supenantant.  Moreover, SLPI pretreated monocytes produced more IL-6 and IL-10 than untreated monocytes and restored the levels of IkB.  Conclusion:  the present results strongly suggest that SLPI is an immunomodulator. Indeed, plasma SLPI and lymphocyte proliferation could be used as a marker to follow up lung cancer and COPD patients.